GeneThera Utilizes PURIVAX Technology to Develop Vaccine for Chronic Wasting Disease.

Business Editors/Health/Medical Writers

WHEAT RIDGE, Colo.--(BUSINESS WIRE)--Oct. 14, 2003

GeneThera, Inc. (OTCBB:GTHA) announced today that development of a vaccine for Chronic Wasting Disease (CWD) is underway.

This vaccine works in conjunction with GeneThera's live blood test for CWD. GeneThera will be able to detect the efficacy of their vaccine within a short period of time utilizing their genetic testing method.

Because of the genetic nature of this vaccine and test, GeneThera will be able to speed up the process of clinical trials immensely. With traditional vaccines, an inoculated strain of the virus is injected into the host, and 6-8 weeks later an immunoresponse is triggered and the effectiveness of the vaccine is measured. In contrast, GeneThera's vaccine works on a genetic level. A highly purified strand of coded RNA is injected into the host and is transported to the genetic mechanism responsible for the disease. Once here, the RNA strand attaches itself to the corresponding code in the gene and prevents the virus from replicating and in turn the animal will not show signs of the disease.

Dr. Antonio Milici, CEO of GeneThera, Inc., stated, "This is the first of many therapeutic vaccines using our PURIVAX(TM) technology that we are developing at GeneThera." He added, "In the coming months, we hope to move into clinical trials and begin testing our vaccine on elk and deer."

PURIVAX(TM) is a method by which the vaccines are purified so that they do not harm the recipients. This system of purification prevents any side effects that might be involved with the injections of the vaccines. This is extremely important, as earlier attempts with therapeutic vaccines have been known to harm the animal instead of curing it.

About GeneThera

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colo. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7; and Johnne's Disease, diseases affecting cattle worldwide. Future plans include all infectious disease potentially affecting domesticated livestock as well wildlife intended for human consumption, particular priority being given to Mad Cow and Foot & Mouth diseases in cattle.

GeneThera's PURIVAX(TM) is a revolutionary system that dramatically improves biological purity and viral titer of recombinant adenovirus and AAV vectors. PURIVAX(TM) completely eliminates toxic side effects associated with adenoviruses and AAV vectors making it possible to develop highly immunogenic and safe recombinant DNA vaccines.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.